Enzalutamide Rechallenge Yields Small PFS Boost in Metastatic Prostate Cancer
In patients with metastatic castration-resistant prostate cancer (CRPC) who have progressed on enzalutamide (Xtandi), those who continued the treatment in combination with docetaxel and prednisolone saw improved progression-free survival (PFS), the phase IIIb PRESIDE study found. Median PFS was 9.53 months with the the enzalutamide-based combination compared with 8.28 months in those treated with placebo […]
Women at Higher Odds for Side Effects From Some Cancer Treatments
Latest Cancer News TUESDAY, Feb. 15, 2022 (HealthDay News) Gender differences extend to cancer treatments, with women having a higher risk of severe side effects from certain treatments than men, a new study finds. Previous research concluded women tend to have more side effects from chemotherapy, and this new paper shows the same is true […]
Initiative to map the cholangiocarcinoma (CCA) landscape in Europe will help improve patient outcomes
Bile duct cancer, also known as cholangiocarcinoma (CCA), is a rare cancer often diagnosed only at an advanced stage. A comprehensive analysis of diagnostic, prognostic, and therapeutic aspects of over 2,200 patients in Europe now provides a valuable knowledge base for raising awareness and managing CCA to improve outcomes. This study is reported in the […]
FDA Panel Rejects Lilly’s Cancer Drug Tested Only in China
Latest Cancer News FRIDAY, Feb. 11, 2022 (HealthDay News) A new lung cancer drug that has only been tested in China was soundly rejected by an advisory panel to the U.S. Food and Drug Administration on Thursday. Known as sintilimab, the treatment is a type of immunotherapy that unleashes the immune system to attack tumors. […]
Immune-Based Therapy Shows Promise Against Advanced Breast Cancers
Latest Cancer News WEDNESDAY, Feb. 9, 2022 (HealthDay News) An experimental therapy that harnesses the body’s tumor-fighting immune cells may be effective for some women with advanced breast cancer, early research suggests. The findings come from an ongoing trial at the U.S. National Cancer Institute (NCI). It is testing a new approach to treating women […]
Another PARP Inhibitor Active in BRCA-Mutant Prostate Cancer
A third of patients with previously treated BRCA-mutant metastatic castration-resistant prostate cancer (mCRPC) responded to the PARP inhibitor niraparib (Zejula), a prospective phase II study showed. The results showed that 26 of 76 patients with measurable disease had objective responses, 35 of whom had at least a 30% decrease in tumor size. An exploratory analysis […]
White House Relaunches Cancer Moonshot Initiative
Latest Cancer News THURSDAY, Feb. 3, 2022 (HealthDay News) President Joe Biden announced Wednesday that he is giving a new push to the cancer moonshot initiative that he first led during the Obama administration. In his announcement, Biden said the program would aim to boost prevention, screening and research with a target of reducing the […]
New path to treat advanced triple-negative breast cancer
A new study by researchers at Yale Cancer Center shows inhibition of the CECR2 gene prevents triple-negative breast cancer from advancing or metastasizing. The discovery is an early step in finding new therapeutics for triple-negative breast cancer (TNBC), one of the most difficult disease sub-types to treat. The findings are published online today in the […]
Deadly Colon Cancers Increasing in Younger Americans – MedicineNet Health News
Latest Cancer News By Amy Norton HealthDay Reporter TUESDAY, Feb. 1, 2022 Yet another study is chipping away at the idea that colon and rectal cancers are diseases of older age: In the past couple decades, Americans younger than 40 have shown the steepest rise in advanced cases of these cancers. The research adds to […]
AI for Radiation Therapy Works, but Is it Fully Trusted?
The use of artificial intelligence in creating radiation treatment plans for prostate cancer appeared to be a success, according to a blinded, head-to-head study. Overall, radiation oncologists considered the vast majority — 89 of 100 — of machine learning (ML)-generated plans clinically acceptable for treatment, reported Thomas Purdie, PhD, and colleagues at Princess Margaret Cancer […]